Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach
- 10 August 2023
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 260, 115713
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Structural basis for CARM1 inhibition by indole and pyrazole inhibitorsBiochemical Journal, 2011
- Epigenetics in Alternative Pre-mRNA SplicingCell, 2011
- Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancersInternational Journal of Cancer, 2010
- Design, Synthesis and Biological Evaluation of Carboxy Analogues of Arginine Methyltransferase Inhibitor 1 (AMI‐1)ChemMedChem, 2010
- 1,2-Diamines as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1)Bioorganic & Medicinal Chemistry Letters, 2009
- CHARMM: The biomolecular simulation programJournal of Computational Chemistry, 2009
- N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1)Bioorganic & Medicinal Chemistry Letters, 2009
- Protein Arginine Methylation in Mammals: Who, What, and WhyMolecular Cell, 2009
- Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1)Bioorganic & Medicinal Chemistry Letters, 2008
- Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonistsJournal of Medicinal Chemistry, 1988